Since the beginning of the COVID-19 pandemic, an unprecedented global effort has resulted in the rapid emergence, and early regulatory authorization or approval, of multiple vaccines for use in humans 1. These data support the development of SpFN-ALFQ as a broadly protective, next-generation SARS-CoV-2 vaccine. Dose-dependent SpFN-ALFQ vaccination protected against SARS-CoV-2-induced disease and viral replication following intranasal B.1.1.7 or B.1.351 challenge, as evidenced by reduced weight loss, lung pathology, and lung and nasal turbinate viral burden. Neutralizing antibody titers were equivalent against WA1, B.1.1.7, and B.1.351 variants following two high dose vaccinations. Binding antibody responses were comparable between high- and low-dose groups. Animals were intranasally challenged at week 11. SpFN-ALFQ was administered as either single or double-vaccination (0 and 4 week) regimens, using a high (10 μg) or low (0.2 μg) dose. We evaluated whether a SARS-CoV-2 spike ferritin nanoparticle vaccine (SpFN), adjuvanted with the Army Liposomal Formulation QS21 (ALFQ), conferred protection against the Alpha (B.1.1.7), and Beta (B.1.351) VOCs in Syrian golden hamsters. The emergence of SARS-CoV-2 variants of concern (VOC) requires adequate coverage of vaccine protection. Npj Vaccines volume 6, Article number: 129 ( 2021) A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |